Clinical Trials Directory

Trials / Unknown

UnknownNCT01758016

Haptoglobin and Diabetes Complications in Pregnancy

Status
Unknown
Phase
Study type
Observational
Enrollment
400 (estimated)
Sponsor
Rambam Health Care Campus · Academic / Other
Sex
Female
Age
Healthy volunteers
Not accepted

Summary

Pregnancies of patients with Diabetes are associated with increase adverse pregnancy outcome . The risk for vascular complications including: Intra uterine growth restriction (20%), hypertension (31%), preeclampsia (15%), eclampsia and placental abruption are significantly greater than those in background populations. The risk of developing vascular complications in diabetes pregnancies although is correlated with the severity and length of the disease is not fully understood. Enhanced oxidation has been suggested to be the underlying abnormality responsible for some of the complications of diabetes. Haptoglobin (Hp) is an abundant plasma glycoprotein produced in the liver. The best understood function of Hp is to bind free hemoglobin (Hb) released from red blood cells. Extracorpuscular Hb is a potent Fenton reagent.capable of of inflicting oxidative tissue damage. Hp binds to Hb and serves to inhibit the oxidative potential of Hb by preventing the release of heme iron. The haptoglobin (Hp) gene at chromosomal locus 16q22 is polymorphic, with two common alleles denoted 1 and 2. the prevalence of Hp 1-1, Hp 1-2 and Hp 2-2 genotypes is approximately 16%, 48% and 36%, respectively. In the western world. A total of five independent longitudinal studies have demonstrated that DM individuals with Hp 2-2 genotype have a two to five-fold increased risk of CVD as compared to DM individuals without the Hp 2-2 genotype We sought to determine whether HP genotype plays important role in development of vascular complications in pregastational pregnancies. and whether Hp genotype 2-2 is a risk factor for developing gestational diabetes (GDM)

Conditions

Timeline

Start date
2012-11-01
Primary completion
2016-12-01
Completion
2017-06-01
First posted
2012-12-31
Last updated
2015-10-07

Locations

3 sites across 1 country: Israel

Source: ClinicalTrials.gov record NCT01758016. Inclusion in this directory is not an endorsement.